News argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 11/07/2025 BST			5-day change	1st Jan Change
480.50 ^EUR	-1.01%		+2.87%	-19.92%

07-08	Deutsche Bank Upgrades Argenx to Buy, Raises PT	MT
07-08	European shares flat as investors assess new US tariff proposals	RE

Deutsche Bank Upgrades Argenx to Buy, Raises PT	07-08	MT
European shares flat as investors assess new US tariff proposals	07-08	RE
Unnatural Products, Inc. Announces Multi-Target Collaboration with argenx to Develop Oral Macrocyclic Peptide Therapeutics	07-01	CI
Argenx to Move ARGX-119 Development to Registrational Study of Congenital Myasthenic Syndromes	06-30	MT
Argenx SE Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	06-30	CI
Argenx : argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	06-30	PU
Argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	06-30	GL
Argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes	06-30	AQ
Argenx Obtains Approval in EU for Monotherapy for Rare Autoimmune Disease	06-23	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	06-20	MT
Argenx SE Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-20	CI
Argenx Receives European Commission Approval for Monotherapy to Treat Neuromuscular Disorder	06-20	MT
Argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-20	GL
Argenx : argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-19	PU
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06-16	MT
Argenx Says Vyvgart Improved Muscle Strength in Phase 2 Myositis Trial	06-11	MT
Argenx SE Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease	06-11	CI
Argenx : argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	06-11	PU
Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren'S Disease	06-10	RE
Argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	06-10	GL
Argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease	06-10	AQ
Argenx SE Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08:40 AM	06-10
Argenx : argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference	06-03	PU
Argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference	06-03	GL
Scholar Rock Holding Corporation Announces Appointment of Rebecca Mcleod as Chief Brand Officer	06-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Filters